Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present BioPharmX Corporation (OTC: BPMX).

Full DD Report for BPMX

You must become a subscriber to view this report.


Recent News from (OTC: BPMX)

Factors of Influence in 2018, Key Indicators and Opportunity within Energy Transfer Equity, Mednax, BioPharmX, Owens & Minor, SunPower, and Convergys - New Research Emphasizes Economic Growth
NEW YORK, May 10, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Energy Transfer Equity, L.P. (NYSE:ETE), Mednax, Inc (NYSE:MD), BioPharmX ...
Source: GlobeNewswire
Date: May, 10 2018 07:30
BioPharmX Reports Fourth Quarter and Full Year 2018 Financial Results
MENLO PARK, Calif. , April 26, 2018 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company developing products for the dermatology market, today reports financial results for the quarter and year ended January 31, 2018 . ...
Source: PR Newswire
Date: April, 26 2018 16:15
Today's Research Reports on Trending Tickers: BioPharmX and MediWound
NEW YORK, NY / ACCESSWIRE / March 21, 2018 / Stock markets rallied Tuesday on gains from the energy and consumer discretionary sector. Wall Street appears to be eagerly awaiting details from the Federal Reserve's upcoming policy meeting. As per CME Group's FedWatch tool, as of Tuesday, mark...
Source: ACCESSWIRE IA
Date: March, 21 2018 08:00
BioPharmX Cancels Presentation at Oppenheimer's 28th Annual Healthcare Conference Due to Severe Weather
MENLO PARK, Calif. , March 20, 2018 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company developing dermatology products, today announces that it has cancelled its presentation at Oppenheimer's 28 th Annual Healthcare Conference in New Yor...
Source: PR Newswire
Date: March, 20 2018 20:30
U.S. Patent and Trademark Office Awards BioPharmX Patent Protection for Novel Tetracycline-class Topical Drug Compositions
MENLO PARK, Calif. , March 20, 2018 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company developing products for the dermatology market, today announced the U.S. Patent and Trademark Office has granted the first in what the company expects w...
Source: PR Newswire
Date: March, 20 2018 09:15
Key events next week - healthcare (continued #1)
Tuesday (3/20): Oppenheimer (continued). BioLineRx (NASDAQ: BLRX ); Aerie Pharmaceuticals (NASDAQ: AERI ); United Therapeutics (NASDAQ: UTHR ); Addus HomeCare (NASDAQ: ADUS ); Centene (NYSE: CNC ); Quorum Health (NYSE: QHC ); Pfenex (NYSEMKT: PFNX ); SELLAS Life Sciences (NASDAQ: SLS...
Source: SeekingAlpha
Date: March, 16 2018 10:26
BioPharmX to Present at Oppenheimer's 28th Annual Healthcare Conference
MENLO PARK, Calif. , March 14, 2018 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company developing dermatology products, today announces that it will present its updated corporate presentation at Oppenheimer's 28 th Annual Healthcare Confe...
Source: PR Newswire
Date: March, 14 2018 09:15
BioPharmX to Present at 30th Annual ROTH Conference
MENLO PARK, Calif. , March 5, 2018 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company developing dermatology products, today announces that it will present its updated corporate presentation at the 30 th Annual ROTH Conference in Orange Count...
Source: PR Newswire
Date: March, 05 2018 09:15
Investor Expectations to Drive Momentum within Graphic Packaging Holding, Invitation Home, Teradyne, Dean Foods, Valley National, and BioPharmX - Discovering Underlying Factors of Influence
NEW YORK, Feb. 07, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Graphic Packaging Holding Company (NYSE:GPK), Invitation Home Inc. (NYSE:...
Source: GlobeNewswire
Date: February, 07 2018 08:15
BioPharmX To Present Data On New Fluorescence Lifetime Imaging Microscopy to Measure How Effectively Topically Applied Minocycline Reaches Targets in Skin
MENLO PARK, Calif. , Jan. 26, 2018 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company developing dermatology products, today announced that a revolutionary technique to measure how effectively a single dose of topically applied minocycline...
Source: PR Newswire
Date: January, 26 2018 09:15

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-140.1860.19320.1950.1847112,318,954
2018-05-130.19330.1860.19330.183,806,378
2018-05-120.19330.1860.19330.183,806,378
2018-05-110.19330.1860.19330.183,806,378
2018-05-100.1980.1920.1990.192,775,531

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator

Short Analysis provided by Squeeze Report. Get a complete short report on BPMX.


About BioPharmX Corporation (OTC: BPMX)

Logo for BioPharmX Corporation (OTC: BPMX)

BioPharmX, Inc. provides innovative drug delivery products through its unique, patented platform technologies for pharmaceutical and OTC applications.

 

Contact Information

 

 

Current Management

  • James Pekarsky / CEO, CFO, Treasurer
  • Anja Krammer / President, Secretary
  • Stephen Morlock / Director, Business Control
  • Kin Foong Chan / Research amp Development
  • James Pekarsky / Chairman
  • Michael Hubbard /
  • Anja Krammer /

Current Share Structure

  • Market Cap: $3,746,409 - 03/20/2018
  • Authorized: 100,000,000 - 02/28/2018
  • Issue and Outstanding: 12,026,994 - 02/28/2018

 


Recent Filings from (OTC: BPMX)

Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: April, 26 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 26 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 13 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 09 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 14 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 12 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: January, 16 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: January, 16 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: December, 12 2017
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: December, 07 2017

 

 


Daily Technical Chart for (OTC: BPMX)

Daily Technical Chart for (OTC: BPMX)


Stay tuned for daily updates and more on (OTC: BPMX)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: BPMX)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

OTC Report
@OTCReporter

 

 


Disclaimer: OTC Report publishes reports providing information on selected companies. OTC Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. OTC Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in BPMX is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. OTC Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. OTC Report does not own any shares of BPMX and does not buy, sell, or trade any shares of BPMX. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by OTC Report. All rights reserved. Our Full Disclaimer: http://otc.report/disclaimer/